Urgent Call for UK to Screen All Newborns for Muscle-Wasting Disease

Health Secretary Wes Streeting faces increasing pressure to implement nationwide screening for spinal muscular atrophy (SMA) following a compelling appeal from Giles Lomax, the chief executive of charity SMA UK. This critical decision, which could impact the lives of countless families, was underscored during a meeting on March 4, 2024, alongside former Little Mix singer Jesy Nelson, both of whom have experienced the devastating effects of late SMA diagnoses in their own families.

Lomax emphasized to Streeting that “the clock is ticking” as delays in screening decisions mean more infants are diagnosed with this muscle-wasting condition too late. Currently, babies diagnosed with SMA face significant health challenges due to a genetic defect affecting the SMN1 gene, which is essential for maintaining healthy nerve cells. Without proper treatment initiated at birth, these nerve cells deteriorate, leading to muscle atrophy and potentially severe complications.

The NHS offers three effective treatments that can either correct the faulty gene or substitute the critical protein necessary for muscle function. These treatments can halt the progression of the disease but are most effective when administered shortly after birth. Currently, an estimated 33 babies in the UK are diagnosed too late each year, leaving them reliant on wheelchairs or requiring breathing assistance.

Streeting has indicated that he is considering expanding the current NHS pilot program, which tests only one-third of newborns for SMA. This pilot excludes approximately 163,000 babies annually, leaving them untested to serve as a control group. Experts have criticized this approach as “unethical,” arguing that screening should be universal to ensure that no infant is left vulnerable due to their geographic location.

Lomax expressed frustration over the current screening policy, stating, “Under the current NHS screening pilot, where a baby is born determines whether they are screened for SMA or not. That simply isn’t fair.” He called for a nationwide screening initiative to eliminate disparities based on postcode, urging the Health Secretary to prioritize this issue: “This decision cannot wait. Every month of delay means more babies are diagnosed too late.”

The UK National Screening Committee (UKNSC) previously decided against adding SMA to the newborn screening program in 2018, despite the availability of effective treatments since 2019. Currently, the UKNSC’s pilot program will screen 404,000 newborns in two-thirds of England but will not include babies in certain regions, delaying comprehensive screening until at least 2031.

In contrast, NHS Scotland has already moved forward with its own plans to include SMA in its routine heel prick test starting this spring. Meanwhile, newborns in Wales and Northern Ireland remain excluded from these critical screenings.

The SMA community argues that the evidence supporting universal screening is clear, with many developed nations, including the United States and several European countries, already implementing similar programs. In a statement, Streeting acknowledged the advocacy efforts of families affected by SMA, stating, “Jesy and other campaigners have made a powerful case for doing more on screening.”

He also noted progress is being made towards evaluating a larger-scale trial, which could involve hundreds of thousands of newborns. Streeting hopes to expedite the evaluation process and expand it to encompass all babies rather than the current limited approach.

While families await a decision, they remain hopeful that the Health Secretary will heed the urgent call for action. The lives of many newborns hang in the balance as advocates push for swift implementation of screening measures that can prevent irreversible damage and enhance the quality of life for those affected by SMA.